India Glycols reported a strong operational performance for Q4 FY26, with growth in revenue, EBITDA and profitability supported by margin expansion and improved business mix.
The company reported consolidated revenue from operations of Rs 2,360 crore in Q4 FY26, compared with Rs 2,188.65 crore in the corresponding quarter last year, registering a year-on-year growth of around 8%.
Total income for the quarter stood at Rs 2,360.63 crore, compared with Rs 2,190.24 crore in Q4 FY25.
EBITDA for the quarter came in at Rs 167.12 crore, compared with Rs 147.53 crore in the year-ago period, reflecting a year-on-year increase of around 13%.
EBITDA margin improved to 7.1% from 6.7% in Q4 FY25, indicating better operational efficiency and improved profitability during the quarter.
Profit before tax rose to Rs 112.46 crore, compared with Rs 81.79 crore in the corresponding quarter last year.
Net profit after tax for Q4 FY26 stood at Rs 86.88 crore, compared with Rs 64.02 crore in Q4 FY25, reflecting a year-on-year growth of nearly 36%.
Basic and diluted earnings per share for the quarter stood at Rs 13.64, compared with Rs 10.34 in the year-ago quarter.
For the full year ended March 31, 2026, India Glycols reported revenue from operations of Rs 9,826.63 crore, compared with Rs 9,038.95 crore in FY25, marking a growth of around 9%.
Full-year EBITDA stood at Rs 654.18 crore, compared with Rs 525.49 crore in the previous year, reflecting a growth of around 24.5%. EBITDA margin improved during the year as operating performance strengthened across segments.
Net profit for FY26 came in at Rs 292.76 crore, compared with Rs 230.92 crore in FY25, reflecting a year-on-year increase of around 27%.
The company also benefited from improved contributions from joint ventures, which added around Rs 46 crore during the year.
India Glycols’ FY26 performance reflected broad-based operational improvement without the support of exceptional items or one-time gains. Margin expansion, improved product mix, and stronger contribution from specialty chemicals and bio-based products remained key drivers during the year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.